Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SY-4798 in advanced solid tumors
NCT05498519Phase 1Unknown
- Sponsor
- Shouyao Holdings
- Start
- Apr 2021
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SY-4798 in solid tumor (advanced stage), sponsored by Shouyao Holdings. Primary endpoints: Incidence of dose limiting toxicities and Incidence of adverse events and serious adverse events up to 24 months. Status: unknown.
02
Drugs
SY-4798
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05498519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05498519.